Compared to soluble STING agonists, the STING agonist-loaded lipid NPs significantly improved the expansion of antigen-specific (tetramer+) CD8+ T cells (CD45+CD3+CD8+) when co-administered with ovalbumin antigen (OVA), leading to a markedly higher anticancer effect in terms of survival and tumor growth [83]. This evidence concerns the gene CD8A and neoplasm.